Background: The UK Renal Association (RA) and National Institute for Health and Clinical Excellence (NICE) have published clinical practice guidelines which include recommendations for management of anaemia in established renal failure. Aim: To determine the extent to which the guidelines for anaemia management are met in the UK. Methods: Quarterly data were obtained regarding haemoglobin (Hb) and factors that influence Hb from renal centres in England, Wales, Northern Ireland (EWNI) and the Scottish Renal Registry for the incident and prevalent renal replacement therapy (RRT) cohorts for 2010. Results: In the UK, in 2010 53.6% of patients commenced dialysis therapy with Hb 510.0 g/dl (median Hb 10.1 g/dl). The median Hb of haemodialysis (HD) patients was 11.5 g/dl with an interquartile range (IQR) of 10.5-12.3 g/dl. Of HD patients 84.6% had Hb 510.0 g/dl. The median Hb of peritoneal dialysis (PD) patients in the UK was 11.6 g/dl (IQR 10.6-12.5 g/dl). Of UK PD patients, 87.2% had Hb 510.0 g/dl. The median ferritin in HD patients in EWNI was 444 mg/L (IQR 299-635) and 96% of HD patients had a ferritin 5100 mg/L. The median ferritin in PD patients was 264 mg/L (IQR 148-426) with 86% of PD patients having a ferritin 5100 mg/L. In EWNI the mean Erythropoietin Stimulating Agent (ESA) dose was higher for HD than PD patients (9,020 vs. 6,202 IU/week). Conclusions: Of prevalent HD patients, 52.7% had Hb 510 and 412 g/dl. Of prevalent PD patients, 54.3% had Hb 10.5-12.5 g/dl.
Introduction
This chapter describes UK Renal Registry (UKRR) data relating to the management of anaemia in dialysis patients during 2010. The chapter reports outcomes of submitted variables and analyses of these variables in the context of established guidelines and recommendations.
The renal National Service Framework (NSF) part one [1] and the RA minimum standards document 3rd edition [2] state that individuals with chronic kidney disease (CKD) should achieve a haemoglobin (Hb) of at least 10 g/dl within 6 months of being seen by a nephrologist, unless there is a specific reason why it was unachievable. At present the UKRR does not collect Hb measurements specifically from patients 6 months after meeting a nephrologist. However an indication of the attainment of this standard is given by the Hb of the incident patient population (i.e. the Hb at the start of dialysis). The achievement of these standards is mainly through the use of iron therapy (oral and intravenous) and Erythropoietin Stimulating Agents (ESAs).
The risks associated with low (<10 g/dl) and high (>13 g/dl) Hb are not necessarily equivalent. The European Best Practice Guidelines (EBPG) [3] set a minimum target of 11 g/dl but suggest not to go higher than 12 g/dl in severe cardiovascular disease. The United States Kidney Disease Outcomes Quality Initiative (KDOQI) [4] guidelines set a target Hb range of 11-12 g/dl with a recommendation that the Hb target should not be greater than 13.0 g/dl. The NICE guidelines published in 2006 [5] and the 4th edition of the RA Clinical Practice Guidelines 2006 [6] recommended an outcome Hb of between 10.5 and 12.5 g/dl (with ESA dose changes considered at 11 and 12 g/dl) which allows for the difficulty in consistently narrowing the distribution to between 11 and 12 g/dl. In 2009, a new target Hb range for haemodialysis (HD) patients was recommended by the 5th edition of the Renal Association Guidelines for Haemodialysis patients [7] . This guidance specified that pre-HD Hb concentration should be maintained between 10 and 12 g/dl. As this chapter analyses 2010 data, HD patients have been compared against this revised target.
The 5th edition of the UK Renal Association's Anaemia in CKD guideline [8] was published at the end of 2010 and attempted to unify targets with those published in the 2010 update NICE guideline on anaemia management in CKD [9] . The target outcome Hb for RRT patients on ESA treatment in these guidelines is between 10 and 12 g/dl. Therefore next year's report will use this standard for peritoneal dialysis (PD) and transplant patients on ESA therapy. The KDIGO website [10] is a useful resource for comparison of international anaemia guidelines.
The analyses in this chapter examine how centres comply with the 10-12 g/dl range (HD patients), 10.5-12.5 g/dl range (PD patients) and the attainment of the minimum standard of Hb 510.0 g/dl.
The national and international recommendations for target iron status in CKD used in this chapter remain unchanged from the 2006 UKRR Annual Report. The 2007 Renal Association (RA) Clinical Practice Guidelines Document, revised European Best Practice Guidelines (EBPGII), Dialysis Outcomes Quality Initiative (DOQI) guidelines and UK NICE anaemia guidelines all recommend a target serum ferritin greater than 100 mg/L and percentage transferrin saturation (TSAT) of more than 20% in patients with CKD. RA guidelines and EBPGII recommend hypochromic red cells (HRC) less than 10%. In addition, EBPGII recommends a target reticulocyte Hb content (CHr) of greater than 29 pg/cell. KDOQI recommends a serum ferritin >200 mg/L for HD patients. The NICE guidelines suggest that a hypochromic red cell value >6% suggests ongoing iron deficiency.
To achieve adequate iron status across a patient population, RA guidelines and EBPGII advocate population target medians for ferritin of 200-500 mg/L, for TSAT of 30-40%, for hypochromic red cells of <2.5% and CHr of 35 pg/cell. EBPGII comments that a serum ferritin target for the treatment population of 200-500 mg/L ensures that 85-90% of patients attain a serum ferritin of 100 mg/L.
All guidelines advise that serum ferritin levels should not exceed 800 mg/L since the potential risk of toxicity increases without conferring additional benefit. The KDOQI and NICE guidelines advise against intravenous iron administration to patients with a ferritin >500 mg/L.
Serum ferritin has some disadvantages as an index of iron status. It measures storage iron rather than available iron, behaves as an acute phase reactant and is therefore increased in inflammatory states, malignancy and liver disease and may not accurately reflect iron stores if measured within a week of the administration of intravenous iron. Of the alternative measures of iron status available, HRC and CHr are generally considered superior to TSAT. Both however require specialised analysers to which not all UK renal centres have easy access. Since TSAT is measured infrequently in many centres and most UK centres continue to use serum ferritin for routine iron management, ferritin remains the chosen index of iron status for this report.
Methods
The incident and prevalent RRT cohorts for 2010 were analysed. The UKRR extracted quarterly data electronically from renal centres in England, Wales and Northern Ireland; data from Scotland were provided by the Scottish Renal Registry. Patients receiving dialysis on 31st December 2010 were included in the prevalent analysis if they had been on the same modality of dialysis in the same centre for 3 months. The last available measurement of Hb from each patient from the last two quarters of 2010 was used for analysis. Patients were analysed as a complete cohort and also divided by modality into groups.
For the incident patient analyses, data from the first quarter after starting dialysis were used. Patients commencing RRT on PD or HD were included. Those receiving a pre-emptive transplant were excluded.
The last available ferritin measurement was taken from the last three quarters of the year and analysed for prevalent patients. Scotland is excluded from the analysis as data regarding ferritin is not included in its return.
The completeness of data items was analysed at both centre and country level. As in previous years all patients were included in analyses but centres with less than 50% completeness were excluded from the caterpillar and funnel plots showing centre performance. Centres providing relevant data from less than 20 patients were also excluded from the plots. The number preceding the centre name in each figure indicates the percentage of missing data for that centre.
The data were analysed to calculate summary statistics. These were maximum, minimum and average (mean and median) values. Standard deviations and inter-quartile ranges (IQR) were also calculated. These data are represented as caterpillar plots showing median values and quartile ranges.
The percentage achieving RA and other standards was calculated for Hb. The percentage of patients achieving serum ferritin 5100 mg/L, 5200 mg/L and 5800 mg/L were also calculated. These are represented as caterpillar plots with 95% confidence intervals (CIs) shown.
Longitudinal analysis was performed to calculate overall changes in achievement of standards from 1998 to 2010.
The UK RA Clinical Practice [2, 6] and NICE [5] guidelines in operation at the time these data were collected were as follows:
Patients with CKD should achieve a Hb of at least 10 g/dl within 6 months of being seen by a nephrologist, unless there is a specific reason why it could not be achieved.
Patients with CKD treated with RRT should have a Hb of between 10.5 and 12.5 g/dl.
Patients with CKD should have a serum ferritin greater than 100 g/L and percentage transferrin saturation (TSAT) of more than 20%.
Serum ferritin levels in patients with CKD should not exceed 800 g/L.
For the target Hb range in haemodialysis patients the standard specified by the 5th UK RA Clinical Practice Haemodialysis guideline [7] was used, which specifies:
Haemodialysis patients should have a pre-dialysis Hb concentration between 10 and 12 g/dl.
Data regarding ESAs were collected from all renal centres. Erythropoietin data from the last quarter of 2010 were used. Scotland was excluded from the analysis as data regarding ESA was not included in its return. Centres were excluded if there was <90% completeness of ESA data. Centres reporting fewer than 70% of HD patients or fewer than 50% of PD patients treated with ESAs were considered to have incomplete data and were also excluded from further analysis. It is recognised that these exclusion criteria are relatively arbitrary but they are in part based upon the frequency distribution graph of centres' ESA use. The percentage of patients on ESAs is calculated from these data and incomplete data returns risk seriously impacting on any conclusions drawn.
Data are presented as weekly erythropoietin dose. Doses of darbepoietin were harmonised with erythropoietin data by multiplying by 200 and correcting for frequency of administration less than weekly. No adjustments were made with respect to route of administration.
The ESA data were collected electronically from renal IT systems but in contrast to laboratory linked variables the ESA dose required manual data entry. The reliability depended upon who entered the data, whether the entry was linked to the prescription or whether the prescriptions were provided by the primary care physician. In the latter case, doses may not be as reliably updated as the link between data entry and prescription is indirect.
Results

Haemoglobin Haemoglobin in incident dialysis patients
The Hb at the time of starting RRT gives the only indication of concordance with current anaemia management recommendations in the pre-dialysis (CKD 5
-not yet on dialysis) group.
Patients for conservative care of established renal failure were by definition excluded from the dataset. Patients were similarly excluded if they received a pre-emptive transplant. In the future the UKRR hopes to collect and report CKD 5 data from patients who subsequently commence RRT and for those managed conservatively.
The percentage of data returned and outcome Hb are listed in table 8.1. Twelve centres are not included in this analysis due to either being small centres who submitted data on fewer than 20 patients and/or because data completeness was less than 50%.
The median Hb of patients at the time of starting dialysis in the UK was 10.1 g/dl with 53.6% of patients figure 8 .10. The compliance with the new RA Clinical Practice Guidelines [7] recommended range of 10.0-12.0 g/dl is shown in figure 8 .11. In 2010, 52.7% of prevalent HD patients had a Hb within this target range. The majority of centres complied well with respect to both the minimum and target range Hb standards but it was possible to fall within 2-3 SDs of the mean in the funnel plot (figure 8.12) for a percentage of patients with Hb 510 and 412 g/dl and yet have a poor compliance with percentage of Hb 510.0 g/dl (figure 8.13). This demonstrates that compliance with one standard (Hb 510 and 412 g/dl) can be achieved without compliance with another standard (Hb 510.0 g/dl). Table 8 .3 can be used to identify centres in the funnel plot.
Relationship between Hb in incident and prevalent dialysis patients in 2010
The relationship between the percentage of new and prevalent dialysis (HD and PD) patients with a Hb 510.0 g/dl is shown in figure 8.20. As expected, all centres have a higher percentage of prevalent patients achieving a Hb 510.0 g/dl than incident patients. Overall in the UK, 85.0% of prevalent patients, compared to 53.6% of incident patients, had a Hb 510.0 g/dl in 2010. All centres achieved greater than 90% compliance with a serum ferritin 5100 mg/L for HD patients. The PD population had a lower median ferritin value (264 mg/L, IQR 148-426 vs. 444 mg/L, IQR 299-635 for HD). In 2010, 31 centres reported less than 90% of PD patients compliant with serum ferritin 5100 mg/L.
Changes in ferritin 2001-2010
The compliance with guidelines for ferritin in the HD populations has been 95% or above since 2007. In the PD population the compliance has fluctuated over the last few years, and was 85.9% in 2010. The serial values are shown in figure 8 .37. The difference between the compliance in HD and PD was probably because more PD patients achieve adequate Hb without any iron or ESA therapy. The median serum ferritin outcome over time is shown in figure 8 .38.
Ferritin and length of time on renal replacement therapy In HD (but not PD) patients, the median serum ferritin was greatest in those who had survived longest (figures 8.39 and 8.40).
Erythropoiesis stimulating agents in prevalent dialysis patients Patients treated and dose variation -ESA prescription and modality
Treatment of renal anaemia with ESAs has offered a major way to improve quality of life for dialysis patients. These agents are relatively expensive and thus approaches to achieving normal haemoglobin levels 19  65  M RI  87  382  376  107-816  251-510  96  6  Middlbr  97  255  674  124-1871  341-1068  96  40  Newc  100  246  688  157-1732  433-996  98  41  Newry  99  99  621  90-1058  383-775  95  22  Norwch  97  291  535  83-1275  345-753  94  20  Nottm  100  385  530  227-872  422-621  99  9  Oxford  99  348  301  91-741  195-420  94  4  Plymth  98  122  668  215-1876  465-1125  99  41  Ports  99  441  315  82-733  210-435  93  4  Prestn  99  461  540  89-1423  339-824  94  28  Redng  100  242  517  200-1075  391-684  98  17  Sheff  100  565  480  156-917  350-613  97  10  Shrew  98  183  404  83-952  249-649  95  12  Stevng  99  358  445  156-943  301-610  98  10  Sthend  100  119  322  174-612  263-407  98  3  Stoke  99  276  697  230-1587  491-894  100  34  Sund  99  163  583  202-1935  408-812  99  26  Swanse  100  322  337  65-760  203-497  90  4  Truro  100  140  466  234-1022  355-573  99  8  Tyrone  97  87  829  263-1763  550-1130  99  52  Ulster  100  86  585  279-1055  467-717  100  15  Wirral  66  114  601  266-1167  471-768  99  23  Wolve  100  285  512  145-1082  409-649  97  14  Wrexm  61  44  423  177-869  278-562  100  9  York  94  131  508 Webb/Gilg/Wilkie with the lowest possible doses are desirable. Furthermore, recent studies such as the CREATE and CHOIR studies suggest that driving the haemoglobin levels above 13 g/dl and/or high doses of ESAs per se may be associated with an excess of cardiovascular risk compared to the comparator groups in these and other studies [11, 12] . Table 8 .6 shows the percentage of patients treated and the dose of ESA given in HD patients. Equivalent data for PD patients are shown in table 8.7. As shown in previous reports there is substantial variation in the average doses of ESA prescription used in UK dialysis units. The median dose for prevalent HD patients varied from 4,000 to 12,000 IU/week. In PD patients, in whom target haemoglobin can be achieved with substantially less agent, the median dose varied from 3,000-8,000 IU/week. The mean doses for 2010 prevalent patients in England, Wales and Northern Ireland were 9,020 IU/week for HD and 6,202 IU/week for PD patients.
ESA prescription: age and modality associations
The proportion of patients on an ESA was higher for HD (91%) than PD (74%) and this difference was present and similar across all age bands (figure 8.41). The percentage of the whole cohort which maintained a Hb 510 g/dl without requiring ESA (by age band and modality) is shown in figure 8.42 . Figure 8 .43 shows the percentage of anaemic patients (Hb <10.0 g/dl) receiving an ESA. A minority of patients had a Hb <10 g/dl and appeared to not be receiving ESA therapy. There are several potential explanations for this including some patients being declared unresponsive to ESA therapy and therefore no longer being on treatment, some individuals may have just become anaemic and not yet started therapy, others may have been on ESA treatment but not had it recorded and other patients may have decided not to use ESA because of a history of malignancy.
ESA prescription and gender
Provision of ESA by age and gender for HD and PD patients is shown in figures 8.44 and 8.45. For both modalities across all age ranges, a higher percentage of females were on ESA treatment. In HD patients, 94% of females were receiving ESA therapy compared to 89% of males. In PD patients, 77% of females compared to 72% of males were on ESA treatment. The percentage of patients on ESA by time on RRT and dialysis modality is shown in figure 8 .46. This is a cross-sectional analysis at the final quarter of 2010. Patients who had previously changed RRT modality were still included in this analysis. The proportion of PD patients requiring ESA rises with duration of RRT from 73% after 1 year of PD, to 78% after 10 or more years. This almost certainly reflects the loss of residual renal function. For at least the first 10 years on RRT, a greater percentage of HD patients are receiving ESA treatment than patients on PD at any given time point.
ESA dose and success with guideline compliance
There is no significant relationship between centres' mean ESA dose and median Hb for HD patients (figure 8.47) or compliance with the EPBG minimum Blank cells denote centres excluded from analyses due to low patient numbers or very incomplete dosage data standard for Hb in HD patients (figure 8.48). This is not surprising as the most anaemic patients and those least responsive to ESAs are those given the biggest doses. Figure 8 .49 shows the frequency distribution of weekly ESA dose by treatment modality. It is known that not all patients treated with dialysis who have a Hb above 12 g/dl (HD) or 12.5g/dl (PD) are receiving ESA. It has been suggested that it may be inappropriate to include those patients not receiving ESA within the group not meeting this RA target. There are two reasons: firstly, the high Hb remains outside the control of the clinician, and secondly, the recent trials suggesting that it may be detrimental to achieve a high Hb in renal patients were based only upon patients treated with ESAs [11, 12] .
Figures 8.50 and 8.51 show the percentages of HD and PD patients in each centre whose Hb lies above, within or below the RA guidelines of 10-12 g/dl (HD) or 10.5-12.5 g/dl (PD). These charts also show the proportion of patients with a Hb above the upper limit who were receiving, or were not receiving ESAs. These analyses are restricted to the centres with acceptable ESA returns as stipulated above. These figures show that 31.1% of HD patients had a Hb >12 g/dl. Most of these patients (84.8%) were on ESAs. Over a quarter (25.2%) of PD patients had a Hb >12.5 g/dl, but only 52.8% of these were on ESAs. 
